4572.T Stock - Carna Biosciences, Inc.
Unlock GoAI Insights for 4572.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $636.24M | $1.63B | $1.39B | $2.02B | $1.13B |
| Gross Profit | $465.69M | $1.45B | $1.22B | $1.88B | $941.20M |
| Gross Margin | 73.2% | 89.2% | 87.6% | 93.3% | 83.0% |
| Operating Income | $-2,076,104,000 | $-1,116,978,000 | $-1,269,889,000 | $-531,136,000 | $-1,057,068,000 |
| Net Income | $-2,178,576,000 | $-1,152,895,000 | $-1,349,539,000 | $-534,474,000 | $-1,111,032,000 |
| Net Margin | -342.4% | -70.9% | -97.3% | -26.5% | -98.0% |
| EPS | $-121.64 | $-68.62 | $-99.10 | $-42.10 | $-90.33 |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.
Visit WebsiteEarnings History & Surprises
4572.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 7, 2025 | — | $-28.47 | — | — |
Q3 2025 | Aug 12, 2025 | — | $-29.16 | — | — |
Q2 2025 | May 9, 2025 | — | $-26.13 | — | — |
Q1 2025 | Feb 10, 2025 | — | $-31.07 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-27.39 | — | — |
Q3 2024 | Aug 7, 2024 | — | $-39.84 | — | — |
Q2 2024 | May 10, 2024 | — | $-23.27 | — | — |
Q1 2024 | Feb 9, 2024 | — | $4.52 | — | — |
Q4 2023 | Nov 7, 2023 | — | $-20.12 | — | — |
Q3 2023 | Aug 7, 2023 | — | $-21.46 | — | — |
Q2 2023 | May 10, 2023 | — | $-32.78 | — | — |
Q1 2023 | Feb 10, 2023 | — | $-40.37 | — | — |
Q4 2022 | Nov 7, 2022 | — | $-31.92 | — | — |
Q3 2022 | Aug 5, 2022 | — | $-25.25 | — | — |
Q2 2022 | May 10, 2022 | — | $-1.12 | — | — |
Q1 2022 | Feb 10, 2022 | — | $48.47 | — | — |
Q4 2021 | Nov 8, 2021 | — | $-31.67 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-39.46 | — | — |
Q2 2021 | May 10, 2021 | — | $-23.09 | — | — |
Q1 2021 | Feb 12, 2021 | — | $-37.24 | — | — |
Latest News
Frequently Asked Questions about 4572.T
What is 4572.T's current stock price?
What is the analyst price target for 4572.T?
What sector is Carna Biosciences, Inc. in?
What is 4572.T's market cap?
Does 4572.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4572.T for comparison